TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15454021
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline mouthrinse with oral hygiene instruction (OHI)
Study: 10332346
Drug: Mouthrinse intervention;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthrinse intervention; details on dosage and duration not available.
Study: 8388007
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (1%) administered four times daily
Study: 27432604
Drug: Surotomycin 250
Normalized name: Surotomycin
DrugBank: Surotomycin (DB12076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surotomycin 250 mg twice daily
Study: 27432604
Drug: Vancomycin 125
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 125 mg four times daily
Study: 27432604
Drug: Surotomycin 125
Normalized name: Surotomycin
DrugBank: Surotomycin (DB12076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surotomycin 125 mg twice daily
Study: 16572429
Drug: Remission induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission induction chemotherapy
Study: 10871578
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition (PN) containing conventional amounts of dextrose, amino acids, micronutrients, and lipid (120 kJ/d)
Study: 10871578
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition containing only micronutrients and a small amount of lipid (12 kJ/d)
Study: 9408513
Drug: Oral angiotensin-converting-enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral angiotensin-converting-enzyme (ACE) inhibitors
Study: 8257180
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (r‐HuEpo) administered subcutaneously twice a week
Study: 27075705
Drug: CDP/BPO (clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP/BPO (clindamycin 1%/benzoyl peroxide 5%) once daily gel
Study: 27075705
Drug: CDP (clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP (clindamycin 1%) twice daily gel
Study: 25566615
Drug: Kuntai Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuntai Capsule (KC) combined with gonadotropin-releasing hormone agonist (GnRH-a)
Study: 25566615
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a) alone
Study: 24393456
Drug: Varenicline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (2 mg)
Study: 9840564
Drug: Single-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intramuscular methotrexate (1 mg/kg)
Study: 28671626
Drug: Hypoxia +
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxia + Carbohydrate (200 mL/20 min maltodextrin)
Study: 28671626
Drug: Hypoxia +
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxia + Glutamine (20 g/day) and 8% maltodextrin (200 mL/20 min)
Study: 24491065
Drug: Physical fitness
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical fitness training (supported or unsupported treadmill training; cardiovascular active aerobic training; five times per week, over 4 weeks; each session 50 minutes; total of 20 sessions) in addition to standard rehabilitation treatment
Study: 24491065
Drug: Relaxation sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation sessions (non-cardiovascular active; five times per week, over 4 weeks; each session 50 minutes) in addition to standard rehabilitation treatment
Study: 21137649
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg IM
Study: 16355295
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 75 mg IM
Study: 25008950
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4 g/day)
Study: 12029003
Drug: Atorvastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin plus fish oil
Study: 1653313
Drug: 1:200,000 epinephrine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:200,000 epinephrine-containing anesthetic solution
Study: 1653313
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine hydrochloride solution
Study: 17971261
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg escitalopram
Study: 30522143
Drug: 370 mg
Normalized name: lanolin 370 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 370 mg of standardized Epimedium prenylflavonoid extract
Study: 30522143
Drug: 740 mg
Normalized name: collagen 740 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 740 mg of standardized Epimedium prenylflavonoid extract
Study: 30522143
Drug: 1110 mg
Normalized name: DRAIN,ODORPROOF BONGORT #1110
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1110 mg of standardized Epimedium prenylflavonoid extract
Study: 26660859
Drug: 40 IU
Normalized name: Oxytocin 40 IU/1 ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU of intranasal oxytocin
Study: 21441615
Drug: Co-treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-treatment with valproate
Study: 18636543
Drug: Higher-volume preload
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-volume preload (500 ml/171 kcal)
Study: 18636543
Drug: Lower-volume preload
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-volume preload (250 ml/171 kcal)
Study: 11342902
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with 6 intravesical instillations every 6 months for 2 years
Study: 11342902
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no maintenance therapy
Study: 10480684
Drug: Exogenous hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous hormonal factors (hormone replacement therapy)
Study: 8747798
Drug: Inhaled histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled histamine (PC20 < or = 8.0 mg/ml)
Study: 354916
Drug: Mianserin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (30 mg or 60 mg)
Study: 21712619
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tenoxicam
Study: 29941380
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of ibuprofen
Study: 11385163
Drug: Ticlopidine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine monotherapy (2 x 250 mg daily)
Study: 11385163
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (2 x 250 mg ticlopidine plus 100 mg aspirin daily)
Study: 2493366
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg, at -8 hr; 50 mg, -1 hr)
Study: 772665
Drug: Oral antigen
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antigen (1 ml a day for four weeks)
Study: 772665
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 ml a day for four weeks)
Study: 21615623
Drug: Mosapride 15
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride 15 mg
Study: 18805583
Drug: Oral valganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valganciclovir (900 mg twice daily)
Study: 18805583
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (5 mg/kg twice daily)
Study: 10696837
Drug: Proton-pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitor therapy
Study: 15288916
Drug: Self-administered QLQ-SAT32
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered QLQ-SAT32
Study: 15288916
Drug: Interview-administered QLQ-SAT32
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interview-administered QLQ-SAT32
Study: 11704591
Drug: Ibuprofen treatment
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen treatment in CF subjects
Study: 11704591
Drug: No ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No ibuprofen treatment in CF subjects
Study: 9415633
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (40 mg/day)
Study: 8302450
Drug: PCA (infusor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA (infusor Baxter) with morphine i.v. (basal bolus 0.05 mg/kg, loading doses 1 mg every 6‐15')
Study: 8302450
Drug: PCA (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA (morphine i.v., basal bolus 0.07 mg/kg, bolus PCA 0.007 mg/kg lock‐out 15')
Study: 3518333
Drug: Lignocaine nasal
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine nasal spray
Study: 29763783
Drug: Citalopram (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (2 mg/unit BMI)
Study: 29763783
Drug: Dexamethasone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1.5 mg)/Corticotropin-releasing factor (1 μg/kg)
Study: 17964008
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (ONS) for three months in addition to dietary counselling (DC)
Study: 15684311
Drug: Lapatinib (GW572016)
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib (GW572016) administered orally once daily continuously
Study: 12862418
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose recombinant human IL-12 (rhIL-12) at doses of 10, 30, and 100 ng/kg, administered subcutaneously or intravenously
Study: 12862418
Drug: Melan-A26-35 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melan-A26-35 and influenza matrix58-66 peptides administered intradermally on weeks 1, 2, 3, 4, and 9
Study: 12862418
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rhIL-12 (10-100 ng/kg)
Study: 10568486
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream (50 microg/g) applied twice a day with oral etretinate (50 mg/day)
Study: 10568486
Drug: Oral etretinate
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral etretinate (50 mg/day) alone
Study: 8739825
Drug: Phenobarbital 100
Normalized name: phenobarbital 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital 100 mg orally daily for 8 days
Study: 7033825
Drug: Lisuride (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride (mean daily intake of 4.5 mg)
Study: 7033825
Drug: Bromocriptine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (mean daily intake of 56.5 mg)
Study: 30256747
Drug: Cryopreserved placental
Normalized name: human placental tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryopreserved placental membrane (CPM) applied weekly
Study: 27324887
Drug: RI‐002 (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: RI‐002 (10% Liquid Intravenous Immunoglobulin containing high titer neutralizing antibody to RSV)
Study: 25181918
Drug: Pre-implant LVEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-implant LVEF < 22% (T(low)); n = 128
Study: 25181918
Drug: Pre-implant LVEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-implant LVEF 22% to 28% (T(middle)); n = 121
Study: 25181918
Drug: Pre-implant LVEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-implant LVEF > 28% (T(high)); n = 117
Study: 19155454
Drug: Ready-to-use therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-use therapeutic food (RUTF) - 1 packet per day (92 g, 500 kcal/d) for 3 months in intervention villages.
Study: 9589818
Drug: Salmeterol powder
Normalized name: salmeterol Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol powder 50 micrograms twice daily
Study: 7852670
Drug: Albuterol 180
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 180 micrograms four times daily
Study: 2563409
Drug: L‐alanyl‐L‐glutamine (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐alanyl‐L‐glutamine (54 mg peptide‐N/kg per day)
Study: 2563409
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (alanine‐N and glycine‐N)
Study: 51141
Drug: Amoxycillin 1
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 1 g six-hourly for fourteen days
Study: 17126638
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (250 mL for 7 days)
Study: 15574079
Drug: Albuterol (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (16 mg.day(‐1))
Study: 11350882
Drug: ALVAC-CEA B7.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-CEA B7.1 vaccine alone
Study: 11350882
Drug: ALVAC-CEA B7.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-CEA B7.1 vaccine with GM-CSF
Study: 3296236
Drug: Chemonucleolysis (chymopapain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemonucleolysis (chymopapain injection)
Study: 18488808
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of sildenafil 100 mg
Study: 10847313
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 mg, controlled release)
Study: 1627433
Drug: Oral LMF
Normalized name: drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral LMF (chlorambucil, methotrexate, and fluorouracil) for 6 months followed by BCG skin scarifications monthly for up to 2 years
Study: 6328542
Drug: Oral ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoconazole (200 mg twice daily for 5 days)
Study: 6328542
Drug: Clotrimazole 100
Normalized name: clotrimazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 100 mg vaginal tablets (one per night for 6 days)
Study: 22819520
Drug: Titration based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration based on NOTT guidelines
Study: 22819520
Drug: Constant work-rate
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant work-rate tests at 12 ml/min/kg
Study: 17961726
Drug: Continuation chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation chemotherapy
Study: 7483560
Drug: Occupational exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational exposure to lead compounds
Study: 7483560
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not exposed to lead compounds)
Study: 2137995
Drug: Clobetasole‐17‐propionate cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasole‐17‐propionate cream (topical corticosteroid) applied for 1 week prior to prick tests
Study: 2137995
Drug: Loratadine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (oral H1-antihistamine)
Study: 2137995
Drug: Pseudoephedrine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine (oral alpha 1-adrenoceptor agonist)
Study: 7017685
Drug: Intensive plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive plasma exchange (IPE) combined with conventional anti-rejection therapy
Study: 7017685
Drug: Conventional anti-rejection
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anti-rejection therapy alone (control group)
Study: 26501737
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (Genotropin®, Pfizer Inc.) at a dose of 0.035 mg/kg/day by subcutaneous injection for 24 months
Study: 21815963
Drug: K/Mg solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: K/Mg solution pretreatment (n = 84)
Study: 19054698
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment (high-dose and low-dose)
Study: 17502505
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of amblyopia treatment (other than spectacle wear)
Study: 12177657
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) administration, 4 IU subcutaneously every other day for 3 months
Study: 2112271
Drug: Dipyridamole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (150 mg twice daily)
Study: 2112271
Drug: Aspirin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (25 mg twice daily)
Study: 2112271
Drug: Aspirin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (25 mg twice daily) + Dipyridamole (150 mg twice daily)
Study: 646077
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine and thiopentone
Study: 21091349
Drug: CHX gel
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHX gel 2%
Study: 21091349
Drug: CHX gel
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHX gel after 3 minutes of 24% EDTA gel root surface etching
Study: 1764957
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated naproxen 500 mg (2 tablets at night)
Study: 1764957
Drug: Normal release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal release naproxen 500 mg (1 tablet twice daily)
Study: 6637358
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg kg‐1 cimetidine orally
Study: 6637358
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg kg‐1 cimetidine rectally
Study: 30633223
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation (NMES) therapy for 8 weeks
Study: 20630899
Drug: gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine plus S-1 combination therapy
Study: 17205320
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine patch (14 mg)
Study: 9649660
Drug: Lymecycline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline (300 mg/day for 2 weeks, then 150 mg/day for 10 weeks)
Study: 9649660
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg/day for 2 weeks then 100 mg every other day for 10 weeks)
Study: 19144729
Drug: Combined testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined testosterone (40 mg daily for women, 80 mg twice daily for men) and nutritional supplement (475 kcal/d)
Study: 19144729
Drug: Combined testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined testosterone and nutritional supplement
Study: 17545208
Drug: Computer-based system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based system for assessing tremor using a shape-tracing task on a graphic tablet.
Study: 14970111
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg TID
Study: 11477352
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (2 doses, 6 months apart)
Study: 9570178
Drug: Fludrocortisone acetate
Normalized name: Fludrocortisone Acetate
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fludrocortisone acetate (0.1-0.2 mg)
Study: 3052462
Drug: Theophylline +
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline + Ambroxol (TA) - 700 mg theophylline, 60 mg ambroxol/d for 5 days
Study: 3052462
Drug: Ambroxol (A)
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (A) - 60 mg ambroxol/d for 5 days
Study: 4609556
Drug: 3% hexachlorophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hexachlorophane detergent cream
Study: 4609556
Drug: 2% Irgasan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Irgasan DP 300 detergent solution
Study: 28489032
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D concentrations in critical HFMD group (20.0 ± 8.4 ng/mL)
Study: 26189433
Drug: Lonafarnib 100
Normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lonafarnib 100 mg twice daily for 28 days (group 1)
Study: 26189433
Drug: Lonafarnib 200
Normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lonafarnib 200 mg twice daily for 28 days (group 2)
Study: 26189433
Drug: Lonafarnib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lonafarnib (both doses)
Study: 21389753
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (COMB) - 8 weekly body-mind-spirit group psychotherapy sessions added to pharmacotherapy
Study: 21389753
Drug: Monotherapy (MT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (MT) - pharmacotherapy only